by Raynovich Rod | Jul 1, 2013 | Biopharmaceuticals
Biotech Sector All Green Triggered By ONXX Bid A lagging biotech sector perked up today on the $10B bid for ONXX by Amgen(AMGN). Most Rayno Life Science stocks were up except Amgen which was down 0.19%. This is a tradable rally but one not likely to drive the sector...
by Raynovich Rod | Jun 27, 2013 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
Bond Market Stabilizes A strong bond auction today for the 7 Year Treasury at an interest rate of 1.94% helped support the three day rally easing investor concerns about rising interest rates and liquidation of bonds. European and Japanese stocks were also up. Bond...
by Raynovich Rod | Jun 19, 2013 | BIOgraph, Macro
Downside Risk to Economy Diminished So Less “Extreme Monetary Policy” In the Future? Market Stable with downward bias :S&P flat to down 18 pts-10 Year Bond Yield At 2.28% up 3.9% FED Is Optimistic about the economy: housing, consumer sentiment,...
by Raynovich Rod | Jun 5, 2013 | BIOgraph, Biopharmaceuticals
Market Correction Is Here-IBB at 170 off 2%+ The biotech sector sell-off (IBB at $170) continues today despite an effort to rally in the opening (IBB at $178). The biotech sector now tracks the overall market and is no longer immune to macro issues and economic...
by Raynovich Rod | May 22, 2013 | BIOgraph, Biopharmaceuticals
Biotechs Bounce Back After Deep Dive Unless you were trading at the open today and covered your shorts you could have been whipsawed in a volatile market that had NASDAQ down to the 3425 level. Many biotech stocks recovered today so no technical damage. The IBB was...
by Raynovich Rod | Apr 19, 2013 | 2025 Rayno Biopharmaceuticals Portfolio, BIOgraph
Vertex Pharmaceuticals Gives Biotech Sector A Turbo Boost Vertex (VRTX $82), a laggard in the frothy biotech universe rose an astonishing 58% on positive Phase 2 clinical news from its cystic fibrosis drug VX-661. The study showed statistically significant improvement...
by Raynovich Rod | Apr 17, 2013 | Biopharmaceuticals, Macro
Major Sell-Off Early On April 17–Correction is Here with Some Technical Damage Posted 12.15p EDT, Update at 4:56p The rally yesterday was apparently a head fake as a major sell-off resumed today with the NASDAQ down 2.10% and the S&P down 1.7%. The gold free...
by Raynovich Rod | Apr 12, 2013 | 2025 Rayno Biopharmaceuticals Portfolio, Macro
Biotech and Drug Stocks Remain in the Sweet Spot NAZ Down 0.16% at 3295 at Close A string of market up days was halted today as retail sales and consumer sentiment gave bearish indicators.Commodity stocks were also weak-energy down 1.2%, materials down 1.7%- and there...
by Raynovich Rod | Mar 14, 2013 | Biopharmaceuticals, Macro
Technicals Matter in a MOmentum Market Some important trends are developing in momentum stocks some of which are on in our Life Science Portfolio. As we have written previously many momentum stocks are being driven by media buzz, novel business models and sponsorship...
by Raynovich Rod | Mar 5, 2013 | 2025 Rayno Biopharmaceuticals Portfolio, Macro
FED Fuel Fans Feuer The monetized momentum market rolled on today despite the backdrop of bearish commentary from celebrity pundits and strategists. With the DOW hitting new highs at 14,263 (and forgetting about the 2001 NASDAQ 5000 high which is still 2000 points...
